Three suspected Nipah cases surface in Shivamogga dist

Mangaluru, May 5: The Dakshina Kannada district administration has denotified two containment zones, Sampya in Puttur and Thumbe in Bantwal. They were declared containment zones after one coronavirus positive case was reported from each area.

All the primary and secondary contacts of the patients have completed home quarantine period, said DC Sindhu B Rupesh.

The district administration hitherto had already denotified three other such containment zones based on a report of DHO,  after no new case was reported in the area in the last 28 days.

At present, the district has six containment zones-- Shakthinagara, Boloor, First Neuro Hospital in Mangaluru city, Uppinangady in Puttur, Kasaba and Narikombu in Bantwal taluk.

Mangaluru, Mar 29: The second day of a total clampdown by Dakshin Kannada district had no impact as panic-stricken people rushed to buy essential commodities in markets in the City on Sunday without caring for Social distance to be maintained.

Since the crowd swell within minutes the police were forced to order the shops forcibly as otherwise, it might have led to spread of dreaded killer Coronavirus COVID-19.

The rise in Covid-19 cases in Dakshina Kannada and the neighbouring Kasargod district had forced the district administration to declare on total bandh on Saturday and Sunday but in vain.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.